This presentation provides an overview of Oncolytics Biotech Inc. and its lead product REOLYSIN®. REOLYSIN® is a first-in-class immuno-oncology viral therapy for solid tumors and blood cancers. Recent clinical trials showed REOLYSIN® statistically significantly increased overall survival when combined with chemotherapy for metastatic breast cancer. The company has defined a clinical development plan targeting registration in metastatic breast cancer and is pursuing combination trials to further develop REOLYSIN®'s mechanism of action. Oncolytics Biotech has strengthened its leadership team and secured manufacturing agreements to support late-stage trials and early commercialization.
Oncolytics Biotech presented an investor presentation that summarized their progress with REOLYSIN, a therapeutic reovirus for treating cancer. Key points included:
- REOLYSIN showed statistically significant increased overall survival in a phase 2 trial for metastatic breast cancer.
- The FDA granted REOLYSIN Fast Track designation and the clinical development plan focuses on combinations with chemotherapy, immunotherapy, and targeted therapies.
- Safety data has shown REOLYSIN to be well-tolerated with no maximum tolerated dose reached. Manufacturing is established at commercial scale.
- The patent portfolio and leadership team provide a strong foundation to further develop REOLYSIN as a potential treatment for multiple cancer types.
This investor presentation summarizes Oncolytics Biotech's progress developing its lead product REOLYSIN, a proprietary reovirus for treating cancer. Key points include:
- REOLYSIN showed statistically significant increased overall survival in a phase 2 trial combining it with paclitaxel for metastatic breast cancer.
- The company is preparing for regulatory meetings to discuss a potential registration pathway in breast cancer based on these results.
- Additional clinical studies are investigating REOLYSIN in combination with chemotherapy for pancreatic cancer, immunotherapy with pembrolizumab, and targeted therapies from Celgene.
- REOLYSIN's mechanism of action involves direct killing of cancer cells, stimulation of innate and
This investor presentation summarizes Oncolytics Biotech's REOLYSIN viral therapy program. It highlights statistically significant increases in overall survival seen in phase 2 trials in metastatic breast cancer and pancreatic cancer. The clinical development plan focuses on three pathways: chemotherapy combinations as the first registration pathway, immunotherapy combinations with agents like pembrolizumab, and targeted therapy combinations using agents like pomalidomide. Safety data from over 1,100 patients shows a good toxicity profile. Manufacturing is established at commercial scale and the company has a strong patent portfolio. The leadership team has extensive experience in oncology drug development.
Targovax presentation december 2017 carnegietargovax2017
Targovax provided an overview of its clinical programs for its two immuno-oncology platforms: ONCOS oncolytic virus and TG mutRAS neoantigen vaccine. For ONCOS, interim data from ongoing phase I/II trials in several solid tumors was highlighted. For TG, encouraging survival data from a phase I/II trial in resected pancreatic cancer was summarized. Upcoming clinical readouts and trial initiations in 2017-2018 were outlined for both platforms.
Targovax has two immuno-oncology programs - ONCOS, an oncolytic virus, and TG, a RAS neoantigen vaccine. TG has shown promising results in pancreatic cancer trials, with 20% 10-year survival in previous trials. An ongoing phase I/II trial is validating these results with adjuvant chemotherapy. ONCOS has demonstrated the ability to increase tumor-infiltrating T-cells in early trials. Targovax has a broad clinical program with several upcoming data readouts in 2017-2018 from trials in melanoma, mesothelioma, ovarian/colorectal, prostate, and pancreatic/colorectal cancers.
This document provides an overview of Targovax, a biotech company developing immunotherapies for cancer. It summarizes their two platforms: ONCOS-102, an oncolytic virus, and TG, a neoantigen cancer vaccine targeting RAS mutations. For ONCOS-102, phase 1 data showed it can activate the immune system against tumors. Targovax is conducting multiple clinical trials of ONCOS-102 in combination with other therapies. For TG, earlier phase 1 trials showed a 20% 10-year survival rate in pancreatic cancer patients. A recent phase 1/2 trial in pancreatic cancer showed encouraging survival and safety data. Targovax is seeking a partner to advance TG into a
Targovax is developing two immunotherapy platforms - ONCOS-102, an oncolytic virus, and TG01, a peptide vaccine targeting RAS mutations. Early phase clinical trial data shows promise for both platforms. ONCOS-102 increased tumor-infiltrating CD8+ T-cells in 11 of 12 cancer patients and induced systemic anti-tumor immune responses. TG01 shows a median survival of 33.1 months in a phase I/II pancreatic cancer trial compared to historical controls of 27.6 months. Targovax has initiated six new clinical trials to further evaluate these platforms alone and in combination with other therapies.
Targovax is developing immunotherapies to enable the immune system to kill cancer cells. They have two platforms: oncolytic viruses and peptide vaccines. Their peptide vaccine TG01 showed encouraging 2-year survival data in a Phase I/II trial in pancreatic cancer patients, with a survival rate higher than historical controls. Their oncolytic virus ONCOS-102 is in a Phase I trial in CPI-refractory melanoma patients to see if it can activate the immune system and make those patients responsive to checkpoint inhibitors again. Targovax has multiple clinical readouts expected in 2017 and 2018 that could be value inflection points.
Oncolytics Biotech presented an investor presentation that summarized their progress with REOLYSIN, a therapeutic reovirus for treating cancer. Key points included:
- REOLYSIN showed statistically significant increased overall survival in a phase 2 trial for metastatic breast cancer.
- The FDA granted REOLYSIN Fast Track designation and the clinical development plan focuses on combinations with chemotherapy, immunotherapy, and targeted therapies.
- Safety data has shown REOLYSIN to be well-tolerated with no maximum tolerated dose reached. Manufacturing is established at commercial scale.
- The patent portfolio and leadership team provide a strong foundation to further develop REOLYSIN as a potential treatment for multiple cancer types.
This investor presentation summarizes Oncolytics Biotech's progress developing its lead product REOLYSIN, a proprietary reovirus for treating cancer. Key points include:
- REOLYSIN showed statistically significant increased overall survival in a phase 2 trial combining it with paclitaxel for metastatic breast cancer.
- The company is preparing for regulatory meetings to discuss a potential registration pathway in breast cancer based on these results.
- Additional clinical studies are investigating REOLYSIN in combination with chemotherapy for pancreatic cancer, immunotherapy with pembrolizumab, and targeted therapies from Celgene.
- REOLYSIN's mechanism of action involves direct killing of cancer cells, stimulation of innate and
This investor presentation summarizes Oncolytics Biotech's REOLYSIN viral therapy program. It highlights statistically significant increases in overall survival seen in phase 2 trials in metastatic breast cancer and pancreatic cancer. The clinical development plan focuses on three pathways: chemotherapy combinations as the first registration pathway, immunotherapy combinations with agents like pembrolizumab, and targeted therapy combinations using agents like pomalidomide. Safety data from over 1,100 patients shows a good toxicity profile. Manufacturing is established at commercial scale and the company has a strong patent portfolio. The leadership team has extensive experience in oncology drug development.
Targovax presentation december 2017 carnegietargovax2017
Targovax provided an overview of its clinical programs for its two immuno-oncology platforms: ONCOS oncolytic virus and TG mutRAS neoantigen vaccine. For ONCOS, interim data from ongoing phase I/II trials in several solid tumors was highlighted. For TG, encouraging survival data from a phase I/II trial in resected pancreatic cancer was summarized. Upcoming clinical readouts and trial initiations in 2017-2018 were outlined for both platforms.
Targovax has two immuno-oncology programs - ONCOS, an oncolytic virus, and TG, a RAS neoantigen vaccine. TG has shown promising results in pancreatic cancer trials, with 20% 10-year survival in previous trials. An ongoing phase I/II trial is validating these results with adjuvant chemotherapy. ONCOS has demonstrated the ability to increase tumor-infiltrating T-cells in early trials. Targovax has a broad clinical program with several upcoming data readouts in 2017-2018 from trials in melanoma, mesothelioma, ovarian/colorectal, prostate, and pancreatic/colorectal cancers.
This document provides an overview of Targovax, a biotech company developing immunotherapies for cancer. It summarizes their two platforms: ONCOS-102, an oncolytic virus, and TG, a neoantigen cancer vaccine targeting RAS mutations. For ONCOS-102, phase 1 data showed it can activate the immune system against tumors. Targovax is conducting multiple clinical trials of ONCOS-102 in combination with other therapies. For TG, earlier phase 1 trials showed a 20% 10-year survival rate in pancreatic cancer patients. A recent phase 1/2 trial in pancreatic cancer showed encouraging survival and safety data. Targovax is seeking a partner to advance TG into a
Targovax is developing two immunotherapy platforms - ONCOS-102, an oncolytic virus, and TG01, a peptide vaccine targeting RAS mutations. Early phase clinical trial data shows promise for both platforms. ONCOS-102 increased tumor-infiltrating CD8+ T-cells in 11 of 12 cancer patients and induced systemic anti-tumor immune responses. TG01 shows a median survival of 33.1 months in a phase I/II pancreatic cancer trial compared to historical controls of 27.6 months. Targovax has initiated six new clinical trials to further evaluate these platforms alone and in combination with other therapies.
Targovax is developing immunotherapies to enable the immune system to kill cancer cells. They have two platforms: oncolytic viruses and peptide vaccines. Their peptide vaccine TG01 showed encouraging 2-year survival data in a Phase I/II trial in pancreatic cancer patients, with a survival rate higher than historical controls. Their oncolytic virus ONCOS-102 is in a Phase I trial in CPI-refractory melanoma patients to see if it can activate the immune system and make those patients responsive to checkpoint inhibitors again. Targovax has multiple clinical readouts expected in 2017 and 2018 that could be value inflection points.
Corporate Presentation August 24, 2015
1) Oncolytics Biotech is developing the oncolytic virus REOLYSIN® as a cancer therapeutic. REOLYSIN® has shown to selectively replicate in and kill Ras-activated tumor cells while sparing normal cells.
2) Clinical trials involving over 1,100 patients have demonstrated REOLYSIN®'s favorable safety profile and ability to reduce tumor burden and improve overall survival rates.
3) Ongoing randomized phase 2 studies in ovarian, colorectal, breast, lung, and prostate cancers are evaluating REOLYSIN®'s ability to enhance immune responses and improve long-term clinical outcomes.
Targovax is developing immunotherapies to help the immune system fight cancer. They have six ongoing clinical trials combining their oncolytic adenovirus or peptide vaccines with checkpoint inhibitors or chemotherapy. They expect readouts from four of these trials in 2017-2018, which will be important value inflection points. Encouraging survival data was seen in a Phase I/II trial of their peptide vaccine TG01 in resected pancreatic cancer patients.
Targovax presented its 3Q 2017 results, highlighting ongoing clinical trials with its two platforms: ONCOS-102, an oncolytic virus in Phase I/II trials in combination with other therapies, and TG01, a neoantigen vaccine showing encouraging survival data in a Phase I/II trial in pancreatic cancer. Targovax has a cash runway into 2019 to fund its clinical programs and is listed on the Oslo Stock Exchange with a market capitalization of around NOK 930 million.
Targovax is developing two complementary and highly targeted approaches to cancer immunotherapy: a peptide-based targeted immunotherapy platform for patients with RAS-mutated cancers and a virus-based oncolytic immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes for patients with solid tumors.
Targovax is developing cancer immunotherapies using their TG technology to arm the immune system to fight RAS mutated cancers. Their lead candidate TG01 is in Phase I/II trials in combination with chemotherapy for resected pancreatic cancer, showing promising early survival data. Targovax has a broad clinical program with upcoming data readouts evaluating TG01 in additional cancer types and TG02 entering Phase I trials. Their therapeutic cancer vaccines target specific RAS mutations found in many cancers, offering a potential new treatment approach.
Anti cancer peptide drug conjugates (pd cs) an overviewDoriaFang
Currently, ADC drug research has experienced a pile-up of targets, overlapping indication layouts and similar forms. There is an urgent need for a number of manufacturers to come up with new ideas to solve the existing problems. Some companies have taken an alternative route and laid out peptide-drug conjugate (PDC), which is relatively less competitive.
Advances in triple negative breast cancer (tnbc) targeted therapy drugsDoriaFang
Breast cancer is the most common cancer in women worldwide, with triple-negative breast cancer (TNBC) being the most aggressive type. TNBC lacks effective treatment options. Promising targeted therapies for TNBC discussed in the document include PARP inhibitors, antibody-drug conjugates targeting TROP-2 such as Trodelvy, and CDK4/6 inhibitors such as Trilaciclib. Ongoing clinical trials are investigating these agents, alone and in combination, for treating advanced TNBC.
Targovax presented highlights from Q1 2017, including encouraging survival data from a phase I/II trial of TG01 in pancreatic cancer. 68% of patients were still alive after 2 years, compared to historical rates of 30-53%. Targovax will present further clinical data on TG01 at ASCO in June. The company initiated an exploratory trial of TG01 in colorectal cancer and has six clinical trials ongoing or planned in 2017-2018 across cancer indications. Financially, Targovax has cash of NOK 147M and an operating expenses run rate of NOK 104M annually based on the last four quarters.
The document provides an overview of Targovax's clinical programs for ONCOS-102 and TG01. For ONCOS-102, a Phase I/II trial in ovarian and colorectal cancer in combination with durvalumab was initiated in Q3 2017. Encouraging survival and immune response data was reported from the ongoing Phase I/II trial of TG01 in resected pancreatic cancer. Targovax is developing these programs to boost the effectiveness of immunotherapy and has clinical readouts expected in 2017-2019.
Arming the patient's immune system to fight cancertargovax2017
This document summarizes a presentation by Targovax CEO Øystein Soug at a healthcare conference on December 15, 2016. Targovax is developing immunotherapies to enable the immune system to kill cancer cells, including oncolytic viruses, peptide vaccines, cell therapies, and checkpoint inhibitors. The presentation outlines Targovax's clinical trial pipeline and strategy, including trials of ONCOS-102 in CPI-refractory melanoma and mesothelioma and TG01 in resected pancreatic and colorectal cancers. Near-term value drivers include TG01 two-year survival data in pancreatic cancer in 1H2017 and ONCOS-102 interim data in melanoma in 2H2017.
L'efficacia clinica del trattamento con ixabepilone nel carcinoma mammario me...Merqurio
1) Approximately 30% of women diagnosed with early-stage breast cancer will progress to metastatic breast cancer, for which treatment options are limited after anthracycline and taxane chemotherapy.
2) Resistance to chemotherapy is a major challenge, as responses to subsequent treatments are typically low (20-30%) and last less than 6 months.
3) Ixabepilone is a potential treatment for taxane-resistant metastatic breast cancer due to its activity against microtubules and lack of cross-resistance with other chemotherapies. It may provide an option for patients with limited remaining treatment options.
This document provides an overview of Targovax, a biotechnology company developing immunotherapy treatments for cancer. It summarizes Targovax's two platform technologies: ONCOS-102, an oncolytic virus that selectively infects and lyses cancer cells to trigger an immune response, and TG neoantigen vaccines that target specific cancer mutations to generate T-cells to kill cancer cells. The document outlines Targovax's clinical development plans and timelines across six clinical trials in several cancer indications. It also reviews the company's financial position and shareholder base, noting a strong cash runway into 2019 to complete the planned clinical program.
1706 ir deck full w_appendix v1_cmd_v12_netttargovax2017
The document discusses Targovax's TG01 peptide vaccine platform. TG01 primes the immune system to recognize and destroy cancer cells with RAS mutations through a cocktail of 7 peptides covering common RAS mutations. Earlier trials in pancreatic cancer showed encouraging median and 1-year survival rates compared to historical controls when TG01 was administered with GM-CSF adjuvant. Long-term survival data also correlated with immune responses detected following vaccination.
Targovax is developing two cancer immunotherapy drugs - ONCOS-102, an oncolytic virus, and TG01, a neoantigen vaccine. Data from clinical trials of ONCOS-102 showed it activated patients' immune systems against their tumors. Targovax has an ongoing clinical program testing ONCOS-102 in various cancer types and combinations. TG01 targets RAS mutations in pancreatic cancer and showed encouraging long-term survival rates in previous trials. A recent trial combining TG01 with chemotherapy showed improved median and 2-year survival over historical controls. Targovax is seeking a partner to advance TG01 into a late-stage trial aimed at registration.
James T. Kenney, RPh, MBA, and Michael B. Atkins, MD, prepared useful Practice Aids pertaining to cancer immunotherapies for this CME/MOC/CE/CPE activity titled "Incorporating Cancer Immunotherapies Into the Oncology Treatment Arsenal in Managed Care Settings: Navigating the Complexities of Value Assessment & Cost Optimization in the Era of Immuno-Oncology." For the full presentation, monograph, complete CME/MOC/CE/CPE information, and to apply for credit, please visit us at http://bit.ly/2Er15gR. CME/MOC/CE/CPE credit will be available until December 23, 2019.
1706 ir deck full w_appendix v1_cmd_v6_uten appendixtargovax2017
The document summarizes a capital markets update presentation by Targovax. It discusses Targovax's two immunotherapy platforms - ONCOS-102, an oncolytic virus, and TG01, a peptide cancer vaccine. For ONCOS-102, the virus is injected into tumors where it stimulates an immune response by releasing cancer antigens. TG01 mimics antigens to stimulate "killer" T-cells. Early clinical trial results for ONCOS-102 showed increased tumor-infiltrating T-cells and systemic immune responses in cancer patients. Targovax is pursuing multiple clinical trials to combine its immunotherapies with other treatments.
Peptide drug conjugates (pd cs) new generation of targeted cancer treatmentDoriaFang
As a new generation of targeted cancer treatment, the well-designed PDC not only retains the advantages of traditional drug delivery, but also increases the penetration of tumor drugs and reduces the toxicity to liver and kidney.
1708 2 q presentation v6 uten back-upstargovax2017
This document provides a 3-sentence summary of a presentation by Targovax, a biotech company developing immunotherapies to treat cancer:
Targovax is developing two immunotherapy platforms, ONCOS-102 oncolytic virus and TG01 RAS peptide vaccine, to boost immune responses against cancer and has clinical trials ongoing or planned in several cancer types including pancreatic, melanoma, mesothelioma and others.
The presentation highlights interim clinical data from TG01 showing improved survival outcomes compared to historical controls in resected pancreatic cancer patients and outlines the company's clinical development plans and timelines over the next two years with multiple data readouts expected.
Targovax has sufficient cash runway into
This document discusses the importance and benefits of pharmacogenomics in clinical practice. Pharmacogenomics is the study of how genes affect a person's response to medications. It combines pharmacology and genomics to develop safe and effective medication doses tailored to a person's genetic makeup. Integrating pharmacogenomic testing into practice can help reduce adverse drug reactions, enhance patient outcomes, and lower healthcare costs by avoiding trial-and-error prescribing. Certain populations, such as older adults taking multiple chronic medications, are most likely to benefit from this personalized approach to medication treatment and management. Successful integration requires a partnership approach to help navigate workflow requirements and provide expertise, education and support to providers.
1) The document discusses Targovax's clinical programs using oncolytic viruses and neoantigen vaccines to activate a patient's immune system to fight cancer.
2) Targovax has two lead programs - ONCOS, an oncolytic virus, and TG, a neoantigen vaccine. ONCOS has several ongoing clinical trials and TG has one ongoing trial in colorectal cancer.
3) Preliminary data from a TG trial in pancreatic cancer showed increased median overall and disease-free survival compared to historical controls, suggesting efficacy.
This document provides an overview of Oncolytics Biotech and their lead product, REOLYSIN.
It discusses three clinical development pathways for REOLYSIN: 1) Combinations with chemotherapy to directly lyse tumor cells, 2) Combinations with immunotherapy to activate immune responses, and 3) Combinations with targeted therapies to modulate innate immunity.
For pathway 1, a phase 2 trial showed REOLYSIN in combination with paclitaxel significantly improved overall survival over paclitaxel alone in metastatic breast cancer patients. This provides the basis for a planned 400-patient phase 3 registration study in this indication.
Oncolytics Biotech presented their investor presentation which included the following key points:
1) Oncolytics is developing REOLYSIN, a novel immuno-oncology viral agent for systemic administration that exploits cancer cell lysis and anti-tumor immunity.
2) Additional randomized phase 2 clinical trials in 2017 are expected to generate overall survival data in breast cancer, ovarian cancer, non-small cell lung cancer, and colorectal cancer.
3) The clinical development plan focuses on combining REOLYSIN with chemotherapy for late-stage development and establishing it as a backbone agent combined with immunotherapy.
4) Over 900 patients have been treated with REOLYSIN intravenously with no drug
Corporate Presentation August 24, 2015
1) Oncolytics Biotech is developing the oncolytic virus REOLYSIN® as a cancer therapeutic. REOLYSIN® has shown to selectively replicate in and kill Ras-activated tumor cells while sparing normal cells.
2) Clinical trials involving over 1,100 patients have demonstrated REOLYSIN®'s favorable safety profile and ability to reduce tumor burden and improve overall survival rates.
3) Ongoing randomized phase 2 studies in ovarian, colorectal, breast, lung, and prostate cancers are evaluating REOLYSIN®'s ability to enhance immune responses and improve long-term clinical outcomes.
Targovax is developing immunotherapies to help the immune system fight cancer. They have six ongoing clinical trials combining their oncolytic adenovirus or peptide vaccines with checkpoint inhibitors or chemotherapy. They expect readouts from four of these trials in 2017-2018, which will be important value inflection points. Encouraging survival data was seen in a Phase I/II trial of their peptide vaccine TG01 in resected pancreatic cancer patients.
Targovax presented its 3Q 2017 results, highlighting ongoing clinical trials with its two platforms: ONCOS-102, an oncolytic virus in Phase I/II trials in combination with other therapies, and TG01, a neoantigen vaccine showing encouraging survival data in a Phase I/II trial in pancreatic cancer. Targovax has a cash runway into 2019 to fund its clinical programs and is listed on the Oslo Stock Exchange with a market capitalization of around NOK 930 million.
Targovax is developing two complementary and highly targeted approaches to cancer immunotherapy: a peptide-based targeted immunotherapy platform for patients with RAS-mutated cancers and a virus-based oncolytic immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes for patients with solid tumors.
Targovax is developing cancer immunotherapies using their TG technology to arm the immune system to fight RAS mutated cancers. Their lead candidate TG01 is in Phase I/II trials in combination with chemotherapy for resected pancreatic cancer, showing promising early survival data. Targovax has a broad clinical program with upcoming data readouts evaluating TG01 in additional cancer types and TG02 entering Phase I trials. Their therapeutic cancer vaccines target specific RAS mutations found in many cancers, offering a potential new treatment approach.
Anti cancer peptide drug conjugates (pd cs) an overviewDoriaFang
Currently, ADC drug research has experienced a pile-up of targets, overlapping indication layouts and similar forms. There is an urgent need for a number of manufacturers to come up with new ideas to solve the existing problems. Some companies have taken an alternative route and laid out peptide-drug conjugate (PDC), which is relatively less competitive.
Advances in triple negative breast cancer (tnbc) targeted therapy drugsDoriaFang
Breast cancer is the most common cancer in women worldwide, with triple-negative breast cancer (TNBC) being the most aggressive type. TNBC lacks effective treatment options. Promising targeted therapies for TNBC discussed in the document include PARP inhibitors, antibody-drug conjugates targeting TROP-2 such as Trodelvy, and CDK4/6 inhibitors such as Trilaciclib. Ongoing clinical trials are investigating these agents, alone and in combination, for treating advanced TNBC.
Targovax presented highlights from Q1 2017, including encouraging survival data from a phase I/II trial of TG01 in pancreatic cancer. 68% of patients were still alive after 2 years, compared to historical rates of 30-53%. Targovax will present further clinical data on TG01 at ASCO in June. The company initiated an exploratory trial of TG01 in colorectal cancer and has six clinical trials ongoing or planned in 2017-2018 across cancer indications. Financially, Targovax has cash of NOK 147M and an operating expenses run rate of NOK 104M annually based on the last four quarters.
The document provides an overview of Targovax's clinical programs for ONCOS-102 and TG01. For ONCOS-102, a Phase I/II trial in ovarian and colorectal cancer in combination with durvalumab was initiated in Q3 2017. Encouraging survival and immune response data was reported from the ongoing Phase I/II trial of TG01 in resected pancreatic cancer. Targovax is developing these programs to boost the effectiveness of immunotherapy and has clinical readouts expected in 2017-2019.
Arming the patient's immune system to fight cancertargovax2017
This document summarizes a presentation by Targovax CEO Øystein Soug at a healthcare conference on December 15, 2016. Targovax is developing immunotherapies to enable the immune system to kill cancer cells, including oncolytic viruses, peptide vaccines, cell therapies, and checkpoint inhibitors. The presentation outlines Targovax's clinical trial pipeline and strategy, including trials of ONCOS-102 in CPI-refractory melanoma and mesothelioma and TG01 in resected pancreatic and colorectal cancers. Near-term value drivers include TG01 two-year survival data in pancreatic cancer in 1H2017 and ONCOS-102 interim data in melanoma in 2H2017.
L'efficacia clinica del trattamento con ixabepilone nel carcinoma mammario me...Merqurio
1) Approximately 30% of women diagnosed with early-stage breast cancer will progress to metastatic breast cancer, for which treatment options are limited after anthracycline and taxane chemotherapy.
2) Resistance to chemotherapy is a major challenge, as responses to subsequent treatments are typically low (20-30%) and last less than 6 months.
3) Ixabepilone is a potential treatment for taxane-resistant metastatic breast cancer due to its activity against microtubules and lack of cross-resistance with other chemotherapies. It may provide an option for patients with limited remaining treatment options.
This document provides an overview of Targovax, a biotechnology company developing immunotherapy treatments for cancer. It summarizes Targovax's two platform technologies: ONCOS-102, an oncolytic virus that selectively infects and lyses cancer cells to trigger an immune response, and TG neoantigen vaccines that target specific cancer mutations to generate T-cells to kill cancer cells. The document outlines Targovax's clinical development plans and timelines across six clinical trials in several cancer indications. It also reviews the company's financial position and shareholder base, noting a strong cash runway into 2019 to complete the planned clinical program.
1706 ir deck full w_appendix v1_cmd_v12_netttargovax2017
The document discusses Targovax's TG01 peptide vaccine platform. TG01 primes the immune system to recognize and destroy cancer cells with RAS mutations through a cocktail of 7 peptides covering common RAS mutations. Earlier trials in pancreatic cancer showed encouraging median and 1-year survival rates compared to historical controls when TG01 was administered with GM-CSF adjuvant. Long-term survival data also correlated with immune responses detected following vaccination.
Targovax is developing two cancer immunotherapy drugs - ONCOS-102, an oncolytic virus, and TG01, a neoantigen vaccine. Data from clinical trials of ONCOS-102 showed it activated patients' immune systems against their tumors. Targovax has an ongoing clinical program testing ONCOS-102 in various cancer types and combinations. TG01 targets RAS mutations in pancreatic cancer and showed encouraging long-term survival rates in previous trials. A recent trial combining TG01 with chemotherapy showed improved median and 2-year survival over historical controls. Targovax is seeking a partner to advance TG01 into a late-stage trial aimed at registration.
James T. Kenney, RPh, MBA, and Michael B. Atkins, MD, prepared useful Practice Aids pertaining to cancer immunotherapies for this CME/MOC/CE/CPE activity titled "Incorporating Cancer Immunotherapies Into the Oncology Treatment Arsenal in Managed Care Settings: Navigating the Complexities of Value Assessment & Cost Optimization in the Era of Immuno-Oncology." For the full presentation, monograph, complete CME/MOC/CE/CPE information, and to apply for credit, please visit us at http://bit.ly/2Er15gR. CME/MOC/CE/CPE credit will be available until December 23, 2019.
1706 ir deck full w_appendix v1_cmd_v6_uten appendixtargovax2017
The document summarizes a capital markets update presentation by Targovax. It discusses Targovax's two immunotherapy platforms - ONCOS-102, an oncolytic virus, and TG01, a peptide cancer vaccine. For ONCOS-102, the virus is injected into tumors where it stimulates an immune response by releasing cancer antigens. TG01 mimics antigens to stimulate "killer" T-cells. Early clinical trial results for ONCOS-102 showed increased tumor-infiltrating T-cells and systemic immune responses in cancer patients. Targovax is pursuing multiple clinical trials to combine its immunotherapies with other treatments.
Peptide drug conjugates (pd cs) new generation of targeted cancer treatmentDoriaFang
As a new generation of targeted cancer treatment, the well-designed PDC not only retains the advantages of traditional drug delivery, but also increases the penetration of tumor drugs and reduces the toxicity to liver and kidney.
1708 2 q presentation v6 uten back-upstargovax2017
This document provides a 3-sentence summary of a presentation by Targovax, a biotech company developing immunotherapies to treat cancer:
Targovax is developing two immunotherapy platforms, ONCOS-102 oncolytic virus and TG01 RAS peptide vaccine, to boost immune responses against cancer and has clinical trials ongoing or planned in several cancer types including pancreatic, melanoma, mesothelioma and others.
The presentation highlights interim clinical data from TG01 showing improved survival outcomes compared to historical controls in resected pancreatic cancer patients and outlines the company's clinical development plans and timelines over the next two years with multiple data readouts expected.
Targovax has sufficient cash runway into
This document discusses the importance and benefits of pharmacogenomics in clinical practice. Pharmacogenomics is the study of how genes affect a person's response to medications. It combines pharmacology and genomics to develop safe and effective medication doses tailored to a person's genetic makeup. Integrating pharmacogenomic testing into practice can help reduce adverse drug reactions, enhance patient outcomes, and lower healthcare costs by avoiding trial-and-error prescribing. Certain populations, such as older adults taking multiple chronic medications, are most likely to benefit from this personalized approach to medication treatment and management. Successful integration requires a partnership approach to help navigate workflow requirements and provide expertise, education and support to providers.
1) The document discusses Targovax's clinical programs using oncolytic viruses and neoantigen vaccines to activate a patient's immune system to fight cancer.
2) Targovax has two lead programs - ONCOS, an oncolytic virus, and TG, a neoantigen vaccine. ONCOS has several ongoing clinical trials and TG has one ongoing trial in colorectal cancer.
3) Preliminary data from a TG trial in pancreatic cancer showed increased median overall and disease-free survival compared to historical controls, suggesting efficacy.
This document provides an overview of Oncolytics Biotech and their lead product, REOLYSIN.
It discusses three clinical development pathways for REOLYSIN: 1) Combinations with chemotherapy to directly lyse tumor cells, 2) Combinations with immunotherapy to activate immune responses, and 3) Combinations with targeted therapies to modulate innate immunity.
For pathway 1, a phase 2 trial showed REOLYSIN in combination with paclitaxel significantly improved overall survival over paclitaxel alone in metastatic breast cancer patients. This provides the basis for a planned 400-patient phase 3 registration study in this indication.
Oncolytics Biotech presented their investor presentation which included the following key points:
1) Oncolytics is developing REOLYSIN, a novel immuno-oncology viral agent for systemic administration that exploits cancer cell lysis and anti-tumor immunity.
2) Additional randomized phase 2 clinical trials in 2017 are expected to generate overall survival data in breast cancer, ovarian cancer, non-small cell lung cancer, and colorectal cancer.
3) The clinical development plan focuses on combining REOLYSIN with chemotherapy for late-stage development and establishing it as a backbone agent combined with immunotherapy.
4) Over 900 patients have been treated with REOLYSIN intravenously with no drug
This presentation provides an overview of Oncolytics Biotech and its lead product candidate REOLYSIN. Key points include:
- REOLYSIN is a first-in-class immuno-oncolytic virus being developed for solid tumors and blood cancers. It has a dual mechanism of action selectively killing cancer cells while activating the immune system.
- In a phase 2 trial in metastatic breast cancer, REOLYSIN combined with paclitaxel more than doubled overall survival compared to paclitaxel alone in ER+/PR+/HER2- patients.
- The clinical development plan is pursuing combinations with chemotherapy, immunotherapy agents like Keytruda, and targeted therapies. This includes an ongoing myel
This investor presentation summarizes the development of Oncolytics Biotech's lead product REOLYSIN, a therapeutic reovirus. Key points include:
1) REOLYSIN has demonstrated statistically significant improvements in overall survival for metastatic breast cancer and doubled two-year survival for metastatic pancreatic cancer.
2) The clinical development plan focuses on combination therapies with chemotherapy, immunotherapy agents like pembrolizumab, and targeted therapies/IMiDs to boost REOLYSIN's mechanism of action.
3) Over 1,100 patients have been treated with REOLYSIN which has shown a good safety profile with no maximum tolerated dose reached and mostly mild side effects.
1) The document contains forward-looking statements about Oncolytics Biotech's financial results, business prospects, and the development of REOLYSIN, noting inherent risks and uncertainties.
2) REOLYSIN is a proprietary reovirus isolate that selectively replicates in and lyses tumor cells with an activated Ras pathway. Over 1,100 patients have been treated with REOLYSIN, demonstrating a strong safety profile and evidence of anti-tumor activity.
3) Clinical studies show REOLYSIN can reduce tumor burden, improve overall survival rates compared to standard therapies, and enhance long-term immune responses against residual tumor cells through viral replication and immune-mediated effects.
This document summarizes an investor presentation by Oncolytics Biotech regarding their immuno-oncology agent REOLYSIN. It discusses 3 key points:
1. REOLYSIN's dual mechanism of action turns "cold" tumors "hot" by selectively lysing cancer cells and activating the innate and adaptive immune system.
2. Clinical trials showed REOLYSIN in combination with chemotherapy significantly improved overall survival in patients with metastatic breast cancer and doubled 2-year survival in pancreatic cancer.
3. The company's development plan focuses on combination trials with chemotherapy, immunotherapy agents like Keytruda, and targeted therapies through collaborations with Celgene to advance their lead program in registration trials for metastatic breast cancer
1. The presentation discusses a corporate overview of Oncolytics Biotech including their clinical programs investigating REOLYSIN, a proprietary reovirus, as a cancer therapeutic.
2. Data is presented showing REOLYSIN can reduce tumor burden through direct cytotoxic effects and enhance long-term immune responses. Studies also indicate it may improve overall survival.
3. Oncolytics is developing REOLYSIN for registration in muscle invasive bladder cancer based on ability to show histopathological response. They are also investigating its use in gliomas and other cancers.
This presentation provides an overview of Oncolytics Biotech and its lead product candidate REOLYSIN. Key points include:
- REOLYSIN is an immuno-oncolytic virus that has demonstrated a statistically significant improvement in overall survival for patients with metastatic breast cancer.
- The clinical development plan focuses on combining REOLYSIN with chemotherapy or immunotherapy agents to boost its dual mechanism of action. This includes an ongoing phase 3 study in metastatic breast cancer.
- If approved, REOLYSIN would address a large market as the first systemically delivered oncolytic virus for solid tumors. Oncolytics is preparing for commercial-scale manufacturing.
This investor presentation summarizes Oncolytics Biotech's clinical development plan for REOLYSIN, a viral immunotherapy for cancer. It discusses three pathways: 1) chemotherapy combinations, which are the basis for the first registration pathway in pancreatic cancer. Survival data from several phase 2 studies is expected in 2017. 2) Immunotherapy combinations, including an ongoing study of REOLYSIN with pembrolizumab. 3) Targeted agent/IMiD combinations, such as a collaboration using REOLYSIN with pomalidomide in multiple myeloma. The presentation outlines the mechanism of action of REOLYSIN and how combinations can enhance innate and adaptive immune responses against cancer.
1) TapImmune is developing T-cell immunotherapies focused on breast and ovarian cancers. Their lead candidate, TPIV 200, is in four Phase 2 clinical trials.
2) They are also developing TPIV 110 for HER2-positive breast cancer and plan to file an IND in 2017. Additionally, their PolyStart technology aims to enhance DNA vaccines and is being evaluated preclinically.
3) TapImmune's strategy in 2017 is to complete ongoing Phase 2 trials, seek partners for late-stage development and commercialization, explore combination regimens, and seek opportunities to monetize PolyStart.
REOLYSIN is an oncolytic virus being developed as a cancer therapeutic. It selectively replicates in and kills Ras activated tumor cells. Over 1,100 patients have been treated with REOLYSIN which has shown a good safety profile and evidence of tumor reduction. Clinical trials are ongoing in various cancer types, both as a monotherapy and in combination with chemotherapy and immunotherapy. The goal is to demonstrate tumor reduction and improved overall survival to support regulatory approval. Oncolytics Biotech has a strong patent portfolio and manufactures REOLYSIN at commercial scale.
This corporate presentation provides an overview of Oncolytics Biotech and their lead product REOLYSIN. Key points include:
- REOLYSIN is a proprietary reovirus being studied in five randomized phase 2 clinical trials for various cancers.
- Preclinical research shows REOLYSIN selectively replicates in cancer cells with Ras pathway activation. Over 1,000 patients have been treated safely.
- The company has a strong patent portfolio with over 370 patents worldwide and manufacturing capacity at commercial scale.
- Ongoing studies are evaluating REOLYSIN alone or in combination with chemotherapy to show improved survival outcomes and tumor response rates.
REOLYSIN® shows promise as a cancer therapeutic through two mechanisms of action. It acts as a directed cytotoxin against cancer cells with Ras pathway mutations, reducing tumor burden in clinical trials. It also stimulates anti-tumor immune responses, improving overall survival in some studies compared to chemotherapy alone. Oncolytic Biotech is conducting additional registration trials with tumor reduction and overall survival endpoints to confirm these findings and seek approvals.
1) The document discusses Targovax's clinical programs targeting cancer through immune activation, including their ONCOS oncolytic virus and TG RAS neoantigen vaccine.
2) Early clinical trials of ONCOS-102 demonstrated immune activation and clinical activity in patients with various solid tumors.
3) Targovax is conducting additional trials of ONCOS-102 in combination with checkpoint inhibitors in indications like mesothelioma and peritoneal cancers.
4) The TG vaccine targets mutated RAS neoantigens, which are present in many cancer types, and aims to induce T-cell responses against patient-specific tumors.
This presentation provides an overview of an oncology-focused immunotherapy company. It discusses the company's lead product, NeuVax, which is an immunotherapy targeting HER2-positive breast cancer currently in a Phase 3 clinical trial. The presentation summarizes the clinical development pipeline, mechanism of action involving T-cell activation, positive safety profile established in previous trials, and potential commercial opportunities. It also briefly discusses the company's pipeline of products targeting other cancers, including GALE-301 and GALE-302 which target Folate Binding Protein in ovarian and endometrial cancers.
This presentation provides an overview of an oncology-focused immunotherapy company. It discusses the company's lead product, NeuVax, which is an immunotherapy targeting HER2-positive breast cancer in both the adjuvant and metastatic settings. Key information includes:
- NeuVax is currently in a Phase 3 clinical trial (PRESENT) in the adjuvant setting for HER2 1+/2+ breast cancer patients. Enrollment is complete for the trial.
- An interim analysis of the PRESENT trial is expected in late Q2 2016 which will evaluate safety and futility based on 70 recurrence events.
- Additional clinical trials are exploring NeuVax in combination with Herceptin and in other HER2-positive cancers like
This presentation provides an overview of an oncology-focused immunotherapy company. It discusses the company's lead product, NeuVax, which is an immunotherapy targeting HER2-positive breast cancer in both the adjuvant and metastatic settings. Key information includes:
- NeuVax is currently in a Phase 3 clinical trial (PRESENT) in the adjuvant setting for HER2 1+/2+ breast cancer patients. Enrollment is complete for the trial.
- An interim analysis of the PRESENT trial is expected in late Q2 2016 which will evaluate safety and futility based on 70 recurrence events.
- Additional clinical trials are exploring NeuVax in combination with Herceptin and in other HER2-positive cancers like
This presentation provides an overview of an oncology-focused immunotherapy company. It discusses the company's lead product, NeuVax, which is an immunotherapy targeting HER2-positive breast cancer in both the adjuvant and metastatic settings. Key information includes:
- NeuVax is currently in a Phase 3 clinical trial (PRESENT) in the adjuvant setting for HER2 1+/2+ breast cancer to prevent disease recurrence.
- Additional trials are planned or ongoing to study NeuVax in combination with Herceptin and in other HER2-positive cancers like gastric cancer.
- NeuVax works by stimulating cytotoxic T-cells to seek out and destroy tumor cells expressing HER2 and has shown a good safety profile
This presentation provides an overview of Oncolytics Biotech Inc. and its lead product REOLYSIN®, a novel cancer therapy. Key points include:
- REOLYSIN® is a proprietary reovirus being studied in five randomized Phase II clinical trials for various cancer indications. Interim data has shown increased progression-free and overall survival compared to controls.
- Preclinical research demonstrates REOLYSIN®'s ability to directly kill tumor cells and stimulate anti-tumor immune responses. Combinations with immunotherapies are being explored.
- Over 1,100 patients have been treated with REOLYSIN® to date, which has shown a favorable safety profile both as monotherapy and in
The corporate presentation summarizes Oncolytics Biotech's lead product REOLYSIN, a therapeutic reovirus being studied in multiple clinical trials. Key points include:
- REOLYSIN has been administered to over 1,000 patients safely and shows efficacy against Ras-activated cancers.
- A randomized Phase II trial of REOLYSIN in head and neck cancer, REO 018, showed improved tumor stabilization and shrinkage for those receiving REOLYSIN compared to the control arm.
- Oncolytics intends for REO 018 to support a planned Phase III registration trial of REOLYSIN in head and neck cancer.
Similar to August 2017 Corporate Presentation (20)
This document provides an investor presentation for Oncolytics Biotech regarding their clinical development program and progress with REOLYSIN, an investigational immuno-oncology viral therapy. Recent progress includes statistically significantly increased overall survival in a phase 2 trial of REOLYSIN in combination with paclitaxel in metastatic breast cancer patients. The clinical development plan focuses on evaluating REOLYSIN in combination with chemotherapy, immunotherapy agents, and targeted therapies to potentially boost multiple aspects of REOLYSIN's mechanism of action. Upcoming milestones include an end-of-phase 2 meeting to discuss the registration pathway in metastatic breast cancer.
This document provides an investor presentation for Oncolytics Biotech Inc. summarizing recent progress and the clinical development plan for REOLYSIN, an immuno-oncology viral agent. Key points include:
- REOLYSIN showed statistically significant increased overall survival in a phase 2 trial in metastatic breast cancer when combined with paclitaxel chemotherapy.
- The clinical development plan focuses on combining REOLYSIN with chemotherapy, immunotherapy agents, and targeted therapies to boost its immune-activating mechanism of action.
- Upcoming milestones include presenting pancreatic cancer data at ASCO and holding an end-of-phase 2 meeting to discuss the metastatic breast cancer registration pathway.
- The document outlines Oncolytics Biotech's corporate presentation from September 2016. It discusses the company's oncolytic virus REOLYSIN, its two mechanisms of action, positive clinical trial data showing increased progression-free and overall survival for certain patient groups, evidence of tumor responses including reductions in liver metastases, an upcoming colorectal cancer study, potential in multiple myeloma based on preclinical data, commercial-scale manufacturing, and a strong intellectual property portfolio with over 400 issued patents worldwide. The presentation positions REOLYSIN as a promising cancer therapeutic prepared for late-stage clinical trials.
- The presentation provides an overview of Oncolytics Biotech Inc. and its lead product candidate REOLYSIN®, an oncolytic virus being developed as a cancer therapeutic.
- Data is presented showing REOLYSIN®'s ability to reduce tumor burden through direct cytotoxic effects and stimulate anti-tumor immune responses, improving overall survival in clinical trials.
- Oncolytics has conducted over 30 clinical trials across many cancer types and is preparing registration trials in indications like pancreatic cancer based on favorable results. Manufacturing and a strong patent portfolio were also summarized.
This corporate presentation provides an overview of Oncolytics Biotech Inc. and its lead product REOLYSIN®, a cancer therapy. It discusses ongoing randomized phase II clinical trials in ovarian, colorectal, lung, prostate and breast cancers. Previous clinical trials have shown REOLYSIN® to be generally safe and well-tolerated, with the potential to reduce tumour burden and improve survival. The company has a strong intellectual property portfolio with over 370 patents worldwide and manufacturing capacity at commercial scale. Top-line data readouts from the ongoing randomized studies are anticipated in 2015 which could support preparation for a registration study.
This corporate presentation summarizes Oncolytics Biotech's lead product REOLYSIN, a novel cancer therapy. It discusses ongoing clinical trials of REOLYSIN in combination with chemotherapy in various cancer indications. Positive results are shown reducing tumor burden and improving survival outcomes. Future registration pathways are outlined based on reducing tumor size prior to standard therapies or improving survival when combined with chemotherapy and immune therapies. Over 1,000 patients have been treated with REOLYSIN which has shown to be generally safe and well tolerated.
This presentation provides an overview of Oncolytics Biotech and their lead product REOLYSIN®, a therapeutic reovirus being studied for various cancer indications. Key points include:
- REOLYSIN® has shown selective cytotoxicity against cancer cells with Ras pathway activation and is currently in six phase II randomized clinical trials in cancers like breast, lung, colorectal, prostate, pancreatic, and ovarian.
- Early clinical data shows REOLYSIN® may have immune-mediated anti-tumor activity in addition to direct cytotoxic effects. Combinations with immunotherapy agents are being explored.
- Over 1,000 patients have been treated with REOLYSIN® which has shown a good safety profile with mostly
This corporate presentation provides an overview of Oncolytics Biotech and its lead product REOLYSIN. Key points include:
- REOLYSIN is a proprietary reovirus being tested in combination with chemotherapy in multiple randomized phase 2 clinical trials for various cancers.
- Completed phase 2 trial REO 018 in head and neck cancer showed increased progression-free and overall survival when combined with chemotherapy.
- Ongoing trials include studies sponsored by the NCI in pancreatic, ovarian, lung, and breast cancers.
- REOLYSIN works by selectively replicating in Ras-activated cancer cells and is believed to have a favorable safety profile.
This corporate presentation provides an overview of Oncolytics Biotech and their lead product REOLYSIN. Key points include:
- REOLYSIN is a proprietary reovirus being tested in combination with chemotherapy in seven randomized clinical trials for various cancers. Completed trials show signs of efficacy and a favorable safety profile.
- Preclinical evidence suggests REOLYSIN selectively replicates in Ras-activated cancer cells. Ongoing trials are exploring this mechanism of action and correlating outcomes with Ras pathway biomarkers.
- A randomized Phase 3 trial in head and neck cancer showed increased progression-free and overall survival for patients receiving REOLYSIN plus chemotherapy compared to chemotherapy alone.
This presentation provides an overview of Oncolytics Biotech and its lead product REOLYSIN®, a proprietary reovirus for the treatment of cancers. Key points include:
- REOLYSIN® selectively replicates in and kills Ras-activated cancer cells through a mechanism of action that deactivates the cellular defense protein PKR.
- Oncolytics has an expanding clinical program testing REOLYSIN® across several cancer types both as a monotherapy and in combination with chemotherapy.
- A randomized Phase II head and neck cancer study (REO 018) showed increased progression-free and overall survival for patients receiving REOLYSIN® plus chemotherapy compared to chemotherapy alone.
This presentation provides an overview of Oncolytics Biotech and its lead product REOLYSIN®, a proprietary reovirus for the treatment of cancers. Key points include:
- REOLYSIN® shows efficacy in Ras-activated cancers and has a favorable safety profile. It is being studied in 7 randomized clinical trials in various cancer types.
- Data from a randomized phase 2 trial in head and neck cancer (REO 018) showed improved progression-free survival and tumor responses with the combination of REOLYSIN®, carboplatin and paclitaxel.
- Additional phase 2 studies in lung, prostate, colorectal and other cancers are ongoing to further evaluate REOLYS
Cleades Robinson, a respected leader in Philadelphia's police force, is known for his diplomatic and tactful approach, fostering a strong community rapport.
Methanex is the world's largest producer and supplier of methanol. We create value through our leadership in the global production, marketing and delivery of methanol to customers. View our latest Investor Presentation for more details.
ZKsync airdrop of 3.6 billion ZK tokens is scheduled by ZKsync for next week.pdfSOFTTECHHUB
The world of blockchain and decentralized technologies is about to witness a groundbreaking event. ZKsync, the pioneering Ethereum Layer 2 network, has announced the highly anticipated airdrop of its native token, ZK. This move marks a significant milestone in the protocol's journey, empowering the community to take the reins and shape the future of this revolutionary ecosystem.
The E-Way Bill revolutionizes logistics by digitizing the documentation of goods transport, ensuring transparency, tax compliance, and streamlined processes. This mandatory, electronic system reduces delays, enhances accountability, and combats tax evasion, benefiting businesses and authorities alike. Embrace the E-Way Bill for efficient, reliable transportation operations.
UnityNet World Environment Day Abraham Project 2024 Press ReleaseLHelferty
June 12, 2024 UnityNet International (#UNI) World Environment Day Abraham Project 2024 Press Release from Markham / Mississauga, Ontario in the, Greater Tkaronto Bioregion, Canada in the North American Great Lakes Watersheds of North America (Turtle Island).
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4
World economy charts case
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4study presented by a Big 4
2. Forward Looking Statements
This presentation contains certain forward looking statements relating to the company’s
business prospects and the development and commercialization of REOLYSIN®, a first-in-class
systemically administered immuno-oncology agent for solid tumors and heme malignancies.
These statements are based on management’s current expectations and beliefs and are subject
to a number of factors which involve known and unknown risks, delays, uncertainties and other
factors not under the company’s control which may cause actual results, performance or
achievements of the company to be materially different from the results, performance or other
expectations implied by these forward looking statements.
In any forward looking statement in which Oncolytics Biotech® Inc. expresses an expectation or
belief as to future results, such expectations or beliefs are expressed in good faith and are
believed to have a reasonable basis, but there can be no assurance that the statement or
expectation or belief will be achieved. These factors include results of current or pending clinical
trials, risks associated with intellectual property protection, financial projections, actions by the
FDA/HPB/MHRA and those other factors detailed in the company’s filings with SEDAR and the
Securities and Exchange Commission. Oncolytics does not undertake an obligation to update
the forward looking statements, except as required by applicable laws.
2
3. Rapid Recent Progress
REOLYSIN® statistically significantly increased overall survival
(OS) in metastatic breast cancer (REO + paclitaxel vs. paclitaxel alone)
Granted “Fast Track” designation by the FDA
Strengthened management team:
C-Suite and Business Development
Announced collaboration with Myeloma UK and Celgene on
Phase 1b study of REOLYSIN in combination with Imnovid® or
Revlimid® as a rescue treatment for relapsing myeloma patients
Defined Clinical Development Program & Registration Pathway
Metastatic Breast Cancer
3
4. What is REOLYSIN®?
First-in-class systemically
administered immuno-
oncology viral agent for
solid tumors and
heme malignancies
Non-pathogenic
proprietary isolate of the
unmodified reovirus
4
5. Pelareorep
administered to
patients via IV
In Normal Cells
In Cancer Cells
1. Direct Cell
Lysis
3. Adaptive Immune
Response2. Innate Immune
Response
Release
of TAA
& VAA
T-cell
activationActivation of
NK cells
APC
Release of
inflammatory
cytokines
2. Reolysin replication causes the
release of inflammatory cytokines
( ) which activate Natural Killer (NK)
cells, allowing NK cells to attack
cancer cells.
REOLYSIN® Mechanism of Action
5
More than 40 supporting publications
1. Reolysin selectively replicates in
permissive cancer cells. Upon virus
replication, cancer cells lyse/die
releasing additional virus particles ( )
to infect nearby cancer cells.
In non-cancer cells Reolysin enters
the cells but is unable to replicate and
the virus is actively cleared.
3. Antigen presenting cells (APCs)
display tumor- and viral- associated
antigens ( ) to killer T-cells,
activating an adaptive anti-cancer
immune response.
6. What does REOLYSIN® do?
6
1. Kills cancer cells stressed by
chemo and/or radiation
2. Induces PD-1 & PDL-1 expression
on T-cells and tumor-cells
3. Enhances IMiD targeting
4. Potentiator for all agents
affecting both innate and
adaptive immunity by making
cold tumors hot
7. REOLYSIN® MOA: Lessons Learned
• OS results support Mechanism of Action (MOA)
• OS trumps PFS (progression free survival)
• We’re not the only ones
o Opdivo®, Tecentriq® and Ipilimumab® have been approved on OS
1 Hodi, NEJM 2010, 363:711; 2 Borghaei, NEJM 2015,371:1627; 3 Ferris, NEJM 2016, 375:1856
Melanoma
treated with ICI
vs. chemo
Ipilimumab
SOC
Hodi et.al., NEJM 2010
Ipilimumab
SOC
Overall SurvivalProgression Free Survival
7
9. Clinical Development Plan: Pathways
The clinical development plan addresses drug combinations that
can potentially boost each response of the MOA
1. Path 1 - Chemo combinations (direct cell lysis):
The basis for our metastatic breast cancer registration pathway.
2. Path 2 - Immunotherapy combinations (adaptive immune response):
Approaches with checkpoint inhibitors embodied in the ongoing
REOLYSIN® + pembrolizumab study and possible future collaborations.
3. Path 3 - Combination with IMiDs / targeted therapy (innate immune response):
Currently in combination with Celgene’s Imnovid® & Revlimid® in a first-of-its-
kind immunotherapy trial that aims to modulate the immune system to target
myeloma. Exploring additional collaborations.
9
10. Path 1: Chemotherapy Combinations
Metastatic Pancreatic Cancer (1st Line)
Regulatory Status
o Orphan Drug Designation Granted (FDA / EMA)
o Potential for Fast-Track Designation
o Preparing for End-of-Phase 2 Meeting
Metastatic Breast Cancer
Regulatory Status
o Statistically significant phase 2 OS data
o Seeking scientific advice - potential for
Breakthrough Designation
o Preparing for End-of-Phase 2 Meeting
o Preparing registration pathway
10
11. Path 1: Chemo-Combo / Breast Cancer
• Randomized, non-blinded study, with IV
administered REOLYSIN® given in
combination with paclitaxel versus
paclitaxel alone
• Patients with advanced or metastatic breast
cancer
• Paclitaxel weekly, on days 1, 8 and 15 of a
28-day cycle and test arm with the addition
of REOLYSIN® on days 1, 2, 8, 9, 15 and 16
• 74 patients; powered to 90%
• Endpoints:
• Primary: PFS
• Secondary: OS
• Secondary : ORR
• Secondary: Safety
(IND-213) Phase 2 Data(IND-213) Phase 2 Design
• ORR and PFS similar in both groups
• Statistically significant improvement
in median OS:
• 10.4 months to 17.4 months
• 60 patients presented APC Wild Type
• OS doubled from 10.4 months to
~ 20.9 months
• First immuno-oncology viral-agent to
demonstrate a statistically significant
median OS advantage in a
randomized clinical study
11
12. Path 1: Chemo-Combo / Breast Cancer
Statistically significantly increased overall
survival in metastatic breast cancer in ITT group
Canadian Cancer Trials Group
Test n=36
Control n=38
HR = 0.65
p = 0.1 (powered to 90%)
Test = REO + paclitaxel
Control = paclitaxel
12
13. Path 1: Chemo-Combo / Breast Cancer
Canadian Cancer Trials Group
Test n=31
Control n=29
HR = 0.53
p = 0.03
Test = REO + paclitaxel
Control = paclitaxel
13
Doubled overall survival APC wild type patients
14. Path 1: Chemo-Combo / Breast Cancer
Key Learnings
Consistent with other approved I/O therapies, REOLYSIN® acts as an immune
therapy agent, often with no meaningful improvement in either PFS or ORR
Has the potential to work synergistically with paclitaxel
Next Steps
Seeking scientific advice - potential for Breakthrough Designation
Preparing for End-of-Phase 2 Meeting
Preparing registration pathway in metastatic breast cancer
14
15. 15
115,405
addressable patient
population on
target therapies
(74% of mBC patients)
Source: https://seer.cancer.gov/statfacts/html/breast.html.Accessed on March 28, 2017.
Howlader, Nadia,et al. US Incidenceof Breast Cancer Subtypes Defined by Joint Hormone
Receptor and HER2 Status. Journal of the NationalCancer Institute.Accessed March 28, 2017
3,560,570
breast cancer prevalence, US 2016
2,599,216
Patients with HR+/HER2- Subtype
155,953
Patients diagnosed with stage IV
breast cancer
Path 1: Chemo-Combo / Breast Cancer
16. Path 1: Supporting OS as Registration Endpoint
Doubling 2-year survival in phase 2 studies
Randomized Intention-to-Treat (NCI-8601)
o Carbotax + REO (n=36)
o Carbotax (n=37)
Randomized Excluding Crossover
o Carbotax + REO (n=36)
o Carbotax (n=20)
Single Arm (REO 017)
o REO + Gemcitabine
(n=34)
Reo + gem
2y-OS = 24 %
16
17. Path 2: Immunotherapy Combinations
REO + Pembrolizumab (anti-PD-1 antibody)
in pancreatic cancer (REO 024)
o Establish safety profile
o Final analysis in 2017
Future potential collaborations pending
Rajani, Viruses 2015, 7:588; Noonan, Mol Ther 2016;
Rajani, Mol Ther 2016,24:166
17
18. Path 3: Targeted/IMiD Combinations
REO + Pomalidomide in multiple myeloma
o Establish safety profile
o Ongoing collaboration with Celgene
& Myeloma UK
o Combined with Revlimid® & Imnovid® as a
rescue treatment in myeloma patients
Enhancement of Innate Immune
Response:
REOLYSIN® + IMiDs
REOLYSIN® alone
REOLYSIN® + IMiDs
Release of
inflammatory
cytokines
Increased
activation of
NK cells
Release of
inflammatory
cytokines
Activation of
NK cells
+ IMiDs
18
20. REOLYSIN® and Safety
1,100+ patients treated, 900+ intravenously
No maximum tolerated dose (MTD) reached to date
Monotherapy Toxicity Symptoms
Symptoms frequently observed from day 2 of treatment
and usually lasted < 6 hours
Intravenous local
Toxicities have generally been mild (grade 1 or 2) and included chills, fever,
headache, cough, myalgia, runny nose, sore throat, fatigue, and grade 1 or 2
lymphopenia or neutropenia
Transient grade 3 and 4 toxicities included lymphopenia or neutropenia
20
21. Manufacturing
21
Final formulation produced at 100
Liter-scale under cGMP
> 50,000 standard doses per
production run
Commercial scale manufacturing
agreement with SAFC (part of Merck
Millipore Sigma)
When stored frozen, liquid
formulation is stable for at least five
years (stability testing ongoing)
22. Patent Portfolio
More than 415 patents issued
worldwide, including 61 US and
20 Canadian
Reovirus issue patent claims cover:
• Compositions of matter comprising reovirus
• Through 2028
• Pharmaceutical use of reoviruses to treat
neoplasia and cellular proliferative diseases
• Combination therapy with radiation,
chemotherapy and/or immune suppressants
• Methods for manufacturing reovirus and
screening for susceptibility to reovirus
• Pharmaceutical use of reoviruses in
transplantation procedures
Over 60 pending
applications worldwide
22
24. Experienced Leadership
Matt Coffey, PhD, MBA
Co-founder, Director,
President & CEO
Kirk Look, CA
Chief Financial Officer
EY LLP
Andres Gutierrez, MD, PhD
Chief Medical Officer
Bristol-Myers Squibb
Andrew de Guttadauro
VP of Business Development
Amgen, Biogen, Takeda
Wayne Pisano, MBA
Chairman of the Board, Oncolytics
Former President, Sanofi Pasteur
Angela Holtham, MBA, ICD.D
Nabisco
Hospital for Sick Children
J. Mark Lievonen, CA
Former President, Sanofi Pasteur
Ontario Institute for Cancer Research
William G. Rice, PhD
President & CEO, Aptose Biosciences
President, CEO & Director of Achillion
Bernd R. Seizinger, MD, PhD
Former President & CEO of GPC Biotech
VP of Oncology Drug Discovery, BMS
Non-Executive Directors
Extensive knowledge of oncology/immunotherapy | Public company experience
Strong business development and commercialization expertise
Management
24
25. Milestones
Event Timing
New Leadership Team
Collaboration with Myeloma UK & Celgene
More than doubled 2 year survival in pancreatic cancer
Statistically significantly increased OS in metastatic breast cancer
Fast Track Designation
End-of-Phase 2 Meeting for mBC Mid ’17
Regulatory milestones (including break through status for mBC) 2H
Additional pharma research collaborations (IO’s and IMiD’s) 2H
Projected Registration Partnership 1H 2018
25
26. Market and Capital Data
Exchanges
OTCQX: ONCYF
TSX: ONC
Market Cap (August 4, 2017)
USD $50.5 M
CDN $69.6 M
Shares Outstanding (August 2, 2017) 139,426,222
Warrants (August 2, 2017)
Options (August 2, 2017)
Restricted/performance share units (August 2, 2017)
16,445,000
7,532,827
2,370,388
Fully Diluted (August 2, 2017) 165,774,437
Cash / Cash Equivalents /
Short Term Investments (June 30, 2017)
CDN $16.7 million
USD $13.2 million*
Cash runway End of 2018
26
* Based on FX on June 1, 2017
27. Investment Highlights
REOLYSIN® statistically significantly increased overall survival (OS) in
metastatic breast cancer (REO + paclitaxel vs. paclitaxel alone)
Granted “Fast Track” designation by the FDA
Strengthened management team: C-Suite and Business Development
Unpartnered immuno-oncology viral agent for systemic
administration exploiting dual activity by cancer cell lysis and anti-
tumor immunity
Defined Clinical Development Program & Registration Pathway
Extensive patient safety data showing no added significant toxicity
when used as combination with chemotherapy
Manufacturing at commercial scale with sufficient supplies on hand to
support late- stage development and early commercialization
27